VIPRD
Virtual Institute on Poverty Related Diseases

3 October 2016

Center for HIV/AIDS Vaccine Immunology (CHAVI) has joined the EURIPRED EXTRANET

Based on the success of the CHAVI, two new Centers for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID) have been established at Duke University and at the Scripps Institute to continue to meet the goal of developing an HIV vaccine.
2015-2016 CHAVI-ID Accomplishments:

Induction of Protective Antibodies
Made great progress on mapping two new types of bnAbs-the CD4 mimic antibody type of CD4 binding site antibodies that utilizes the VH1-46 heavy chain, and a V3 glycan bnAb that binds at the apex of the HIV Env trimer
​Made strides in understanding the nature of glycans on native-like trimers such as membrane-bound trimer
Developed new rhesus VH and VL loci maps that are critical to our field’s rhesus macaque antibodyome work
Made a major breakthrough on construction of Simian-Human Immunodeficiency Viruses (SHIVs) by optimizing the Envs for binding to rhesus CD4  
Made steady progress in engaging bnAb germline lineages and in inducing both autologous and heterologous neutralizing antibody lineages
Began testing immunization with sequential Envs as a strategy for recreating with vaccination the events that occur in infection
Gained the ability of a wide range of Env immunogens in vivo to engage the germlines of multiple bnAb germline B cell receptors (BCR)
Developed the concept of Vaccine Transient Immune Modulation (vTim) and our hypothesis of how to safely re-create this immunologic milieu in the setting of vaccination